The ROE as of November 2024 (TTM) for Neurocrine Biosciences, Inc. (NBIX) is 15.68%

According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 15.68%. This represents a change of 296.87% compared to the average of 3.95% of the last 4 quarters.

Neurocrine Biosciences, Inc. (NBIX) Historical ROE (quarterly & annually)

How has NBIX ROE performed in the past?

The mean historical ROE of Neurocrine Biosciences, Inc. over the last ten years is -6.00%. The current 15.68% ROE has changed -361.50% with respect to the historical average. Over the past ten years (40 quarters), NBIX's ROE was at its highest in in the December 2020 quarter at 30.89%. The ROE was at its lowest in in the March 2017 quarter at -31.69%.

Neurocrine Biosciences, Inc. (NBIX) ROE by Quarter and Year

Discovering the peaks and valleys of Neurocrine Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Neurocrine Biosciences, Inc. (NBIX) Average ROE

How has NBIX ROE performed in the past?

The current ROE of Neurocrine Biosciences, Inc. (NBIX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Neurocrine Biosciences, Inc. (NBIX) ROE vs. Peers

How is NBIX’s ROE compared to its peers?

Neurocrine Biosciences, Inc.’s ROE is less than Amphastar Pharmaceuticals, Inc. (22.92%), less than Collegium Pharmaceutical, Inc. (40.81%), greater than Ironwood Pharmaceuticals, Inc. (-7.63%), greater than ANI Pharmaceuticals, Inc. (-1.60%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Alkermes plc (26.49%), greater than Avadel Pharmaceuticals plc (-93.32%), greater than Intra-Cellular Therapies, Inc. (-9.93%), less than Dynavax Technologies Corporation (3.19%), greater than Pacira BioSciences, Inc. (-10.70%), less than Eagle Pharmaceuticals, Inc. (17.39%), less than Prestige Consumer Healthcare Inc. (12.35%), greater than Evotec SE (-16.30%), less than Supernus Pharmaceuticals, Inc. (6.26%),

Build a custom stock screener for Neurocrine Biosciences, Inc. (NBIX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neurocrine Biosciences, Inc. (NBIX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.